HCPCS code J8520 – Capecitabine, oral, 150 mg

Key takeaways

HCPCS code J8520 described capecitabine (Xeloda), oral, 150 mg. CMS terminated it on September 30, 2024, along with J8521, capecitabine, oral, 500 mg.

Suppliers billed J8999 for dates of service from October 1 to December 31, 2024. The drug name, dosage and NDC went in the claim narrative.

From January 1, 2025, capecitabine bills by NDC with no J code on the line. SV101-2 carries S5000 or S5001 only when that NDC has no assigned HCPCS.

J8522, capecitabine, oral, 50 mg, is the reference crosswalk descriptor CMS published. It is not the code a DME MAC supplier submits.

Capecitabine qualifies for Medicare Part B on its own, with no concurrent injectable drug needed. Part D applies when the dispenser cannot bill the DME MAC.

What HCPCS code J8520 covered before CMS pulled it

J8520 was the HCPCS Level II code for capecitabine, oral, 150 mg. HCPCS Level II is the code set the Centers for Medicare and Medicaid Services (CMS) maintains for drugs, supplies and equipment.

J8520 sat in the J8xxx series, the alphanumeric block CMS reserves for oral anti-cancer drugs dispensed in an office or outpatient setting. CMS added the code on January 1, 2000. It terminated the code on September 30, 2024, which makes that the last valid date of service.

Capecitabine itself is a prodrug. The body converts it into 5-fluorouracil, mainly at the tumor site. That mechanism puts it squarely in the oral antineoplastic category. It also explains why its coverage rules differ from intravenous chemotherapy billed under the J0xxx or J9xxx series.

The J8520 record CMS published, field by field

The table below pulls together the reference fields CMS published for J8520. Read every row as history. The code is terminated, so none of it governs a current date of service.

J8520 is deleted, yet lookup sites still show it as current

J8520 is deleted. CMS terminated it on September 30, 2024 and assigned action code N, which means the code gets no further maintenance.

J8521, capecitabine, oral, 500 mg, went on exactly the same date. Neither code is a valid choice for a date of service after September 30, 2024. Neither one is a crosswalk for the other.

Reference databases are where most of the confusion starts. Several still list both codes under a current-year heading, and that heading is only the dataset year. It is not a sign of reactivation.

Open either record and the September 30, 2024 termination date is still sitting there. The CMS HCPCS quarterly update files are the authoritative record of what is live.

Billing a terminated code earns a clearinghouse rejection or an invalid-procedure-code denial from the payer. Because a stored code triggers it rather than a keying slip, a charge master sweep fixes it and a claim-by-claim correction does not. A legacy J8520 entry keeps firing until someone retires it.

Capecitabine’s approved uses set the diagnosis on the claim

Capecitabine (brand name Xeloda, made by Roche) is an oral fluoropyrimidine carbamate. The FDA has approved it for two main indications, colorectal cancer and breast cancer.

Those approved indications drive the claim. The diagnosis you report has to line up with them, or the medical necessity test fails.

• Colorectal cancer: Approved as a first-line treatment for metastatic colorectal cancer, and as adjuvant therapy after surgery for stage III colon cancer.
• Breast cancer: Approved for metastatic breast cancer where the tumor resists both anthracycline- and taxane-based therapy. Also approved with docetaxel for earlier-line disease.
• Mechanism: An oral prodrug converted to 5-fluorouracil (5-FU) mainly at the tumor site, which spares more normal tissue than intravenous 5-FU in some patients.
• Dosing context: Standard cycles run twice-daily oral dosing for 14 days, then a 7-day rest period. The 150 mg tablet J8520 described was one of two strengths on the market.

You do not need oncology training to code this drug. Knowing the approved uses is enough to judge whether a physician’s note supports the claim.

In practice, capecitabine claims pair with ICD-10-CM diagnosis coding from the C18 to C20 range for colorectal malignancy, or C50.x for breast malignancy.

Part B usually pays for capecitabine, not Part D

Part B is usually the right route for capecitabine, and that catches oncology billers off guard. The general rule for a drug the patient swallows at home is Part D.

Capecitabine is one of the carve-outs. It sits inside the Part B oral anti-cancer drug benefit, so a supplier claim is often the right route.

That benefit is set out in CMS Publication 100-04, Chapter 17, Section 80.1, and in Policy Article A52479. The test has nothing to do with what else the patient receives that day. Four statutory criteria have to be met:

• FDA approval: The drug or biological is approved by the FDA.
• Same active ingredient: It shares an active ingredient with a non-self-administrable anti-cancer drug that Part B covers incident to a practitioner’s service. An FDA-approved prodrug also qualifies when the body metabolizes it into that same ingredient.
• Same indication: It treats the same anti-cancer indications as the injectable form, including accepted off-label uses.
• Licensed prescriber: A practitioner licensed by the state to prescribe anti-cancer chemotherapy wrote the order.

Capecitabine clears all four on its own. It is an FDA-approved oral prodrug that the body turns into 5-fluorouracil, the active ingredient in an injectable chemotherapy drug Part B already covers. It treats the same colorectal and breast cancer indications as that injectable form. No second drug has to be given alongside it.

In day-to-day work, two of those four criteria are the ones that actually decide the route. The diagram below runs them in order, then shows what identifies the drug once Part B applies.

Those claims go to the DME MAC under the Oral Anti-Cancer Drugs local coverage determination, LCD L33826. CGS Medicare and Noridian publish matching billing instructions for it.

Only the entity that dispenses the drug may bill for it. That entity has to be licensed in its state and enrolled as a DMEPOS supplier.

Part D picks up the prescription when those conditions are not met. A retail or mail-order pharmacy that does not bill the DME MAC runs it through the patient’s drug plan instead. A non-cancer use fails the third criterion and moves the drug to Part D as well.

Sending a capecitabine claim to Part B when Part D applies is the expensive mistake here. The denial itself arrives fast. Unwinding it means coordinating with the patient’s drug plan, which can add weeks.

So confirm two things before you pick a route: who is dispensing the drug, and how the patient’s coverage is set up.

How to bill capecitabine now that the NDC does the work

The billing method depends on the date of service. Three windows apply, and only the third is open for new claims. All three come from the DME MAC instructions for oral anti-cancer drugs, published by CGS Medicare and Noridian under LCD L33826.

For a current date of service, the walkthrough below produces a submittable Part B claim.

1. Check the date of service first: It decides which of the three windows applies. An old claim being reworked may still belong in the J8999 window.
2. Confirm the Part B route: Check the charted diagnosis against an indication Part B covers injectable 5-fluorouracil for. Confirm your practice is enrolled to bill the DME MAC. If it is not, the prescription runs through the patient’s Part D plan.
3. Pull the matching NDC: Take the 11-digit NDC from the product actually dispensed. It has to agree with the strength, tablet count and package size on the dispensing record.
4. Report the NDC as the drug identifier: Place it in the 2410 LIN segment. Do not add J8520, J8521, J8999 or J8522 to a capecitabine line for a 2025 or later date of service.
5. Set the SV101 values: SV101-1 carries HC. SV101-2 carries S5000 for a generic NDC or S5001 for a brand-name NDC. Use either one only when that NDC has no HCPCS code assigned to it.
6. Report the quantity dispensed: The old arithmetic of one unit per 150 mg went out with the code. Quantity now follows the NDC and the dispensing record.
7. Add the place of service and diagnosis: Use POS 11 for drugs dispensed by the practice, or POS 22 in a hospital-based practice. Link the ICD-10-CM colorectal or breast malignancy code the chart supports.

The NDC is the drug identifier, not a supporting field

Since January 1, 2025 the NDC does the job the J code used to do. It names the manufacturer’s product exactly, down to the strength of each tablet and the count in the package. It has to match what was handed to the patient.

Format the NDC as a continuous 11-digit string. That is 5 digits for the labeler, 4 for the product and 2 for the package.

Some NDCs are printed on the box in a 10-digit format with hyphens. Convert those first, padding the short segment with a leading zero. Send the hyphenated pharmacy format and the clearinghouse will kick the line straight back.

On the 837P, the NDC goes in Loop 2410, segment LIN, with qualifier N4. On a paper CMS-1500 it goes in the shaded part of Box 24A, again after the N4 qualifier.

Claims in the October to December 2024 window worked differently. There the NDC belonged in the narrative, in NTE 2300 or NTE 2400 electronically, or Item 19 on paper.

No modifier brings a deleted code back

No modifier makes a terminated code payable, and a capecitabine line no longer carries a J code at all. The KD requirement that once accompanied J8520 claims is obsolete for this drug. Liability modifiers still behave normally.

Narrative and modifier rules vary by DME MAC, so confirm them with the contractor for your region. CGS Medicare handles Jurisdictions B and C. Noridian handles Jurisdictions A and D.

There is no DME MAC Jurisdiction E, so a policy reference to one signals an unreliable source.

What the chart has to say before the claim goes out

Under Part B, the chart has to support the claim. A claim can be technically complete and still fail an audit if the documentation behind it is thin.

So treat these five items as part of the billing job, not just the clinical one.

• Diagnosis coding: The ICD-10-CM code must identify an indication Part B covers injectable 5-fluorouracil for. Colorectal malignancy codes (C18.0 to C20) or breast malignancy codes (C50.x) are standard. An accepted off-label anti-cancer use also qualifies. A non-cancer use fails the benefit test outright.
• Prescription records: Keep the dispensing record in the patient chart, including drug name, strength, quantity and prescriber. The NDC on the claim must match the dispensed product exactly.
• Medical necessity: The oncologist’s treatment plan should document why capecitabine was selected, the stage and type of malignancy, and that FDA-approved indications are met.
• Part B benefit basis: Nothing in the chart needs to name a concurrent injectable drug. Part B standing rests on capecitabine being an FDA-approved prodrug of 5-fluorouracil, ordered by a prescriber licensed to write anti-cancer chemotherapy. Keep that prescriber detail with the order.
• Prior authorization: Some commercial payers and Medicare Advantage plans require prior authorization for capecitabine. Requirements vary by plan, so confirm before dispensing.

Where a practice dispenses capecitabine to several patients at once, that pairing gets hard to track by hand. This is the job of software for billing teams, which ties each dispensing record to the right claim line before submission.

Five codes touch capecitabine, and none belongs on the line

Five codes come up around capecitabine, and none of them belongs on a current supplier claim line. The table maps each one to what it is actually for.

J8522 is the entry people misread most often. CMS created it as the crosswalk descriptor at the same time the DME MACs told suppliers to stop using J codes for capecitabine altogether.

The old unit arithmetic went out with the codes. A 1,500 mg dose once meant 10 units of J8520, and ten 500 mg tablets meant 10 units of J8521.

There is no equivalent conversion now, because the claim line carries an NDC rather than a milligram-based HCPCS unit. Report the quantity dispensed for that NDC instead.

Before you submit, run these seven checks

Most capecitabine denials trace back to stored data rather than a keying error. Run this list once per claim, and once across the system whenever a coding update lands.

• The charge master, saved claim templates and any dispensing interface feed carry no J8520, J8521 or J8999 entry for capecitabine.
• The DMEPOS enrollment for the dispensing location is active, and the state license is current.
• The ICD-10-CM code on the order names a malignancy the FDA label or an accepted off-label use covers.
• The ordering prescriber is licensed to prescribe anti-cancer chemotherapy, and that detail sits with the order.
• The 11-digit NDC on the line matches the dispensing record on strength, count and package size.
• SV101-2 carries S5000 or S5001 only after someone confirmed that the NDC has no assigned HCPCS code.
• The quantity reported is the quantity dispensed, not a milligram calculation carried over from the old code.

A clean claim for capecitabine is one where all seven hold. Miss one and the line usually comes back within days.

Six denials capecitabine claims still generate

Capecitabine claims have their own denial pattern, and the deletion of J8520 reshaped it. The six errors below account for most of what oncology practices still see on remittance.

Sorting denials by reason code tells a billing lead which of these problems they have. CARC CO-181, procedure code invalid on the date of service, usually points at a stale J code in the charge master.

CARC CO-16, claim lacks information, usually points at the NDC or the narrative instead.

There is no J8520 fee schedule left to look up

There is no current Medicare rate for J8520. A terminated code carries no payment amount, and a capecitabine line no longer carries a J code to price against. Payment on a Part B capecitabine claim follows the DME MAC’s pricing for the NDC submitted.

Suppliers who need a specific allowance should ask their DME MAC. For coding questions, ask the Pricing, Data Analysis and Coding contractor, known as PDAC.

Average Sales Price methodology still governs Part B drugs that do carry a HCPCS code, and CMS republishes those rates every quarter. The CMS ASP pricing files are the source for those figures. Free third-party HCPCS lookup tools are not.

Several run on CMS extracts a decade old, and they return no ASP pricing at all. So no fixed per-unit figure should sit in a charge master without a quarterly refresh against the CMS file.

For Part D claims, capecitabine pricing runs through the patient’s prescription drug plan formulary. The practice submits no claim and receives no direct payment, because the dispensing pharmacy handles that transaction.

If your practice dispenses capecitabine directly and is enrolled as a DMEPOS supplier, you bill the DME MAC as a supplier instead.

How Pabau keeps a capecitabine line from bouncing back

Two failures break capecitabine claims, and both are stored data rather than missing knowledge. One is a terminated code still sitting in the charge master. The other is an NDC that does not match what the patient was handed.

Practice management software like Pabau puts insurance claim submission and tracking in one place. Each claim gets checked for the fields payers require before it leaves, so fewer come back asking for information you already had.

The tracking side matters just as much on a drug like this one. Every submitted claim sits in one list with its status. A run of capecitabine lines stuck on an error then shows up in a morning review, not at month end.

Fewer drug claims coming back for rework

Pabau is practice management software that submits and tracks insurance claims in one place. Each claim gets checked for the fields payers require before it leaves, so your team spends less time reworking denials.

Book a demo

Conclusion

J8520 is history. It ended on September 30, 2024 alongside J8521, and J8999 carried the three months that followed. Capecitabine has been billed by NDC since January 1, 2025. J8522 exists as the 50 mg crosswalk descriptor, and no supplier submits it.

Two risks are left, and neither one is about knowing the rule. The first is a stale J code sitting in a system nobody has swept. The second is a Part B claim filed where Part D applies, which costs weeks to unwind.

Both are worth an afternoon of housekeeping, and both stay fixed once the stored data is right. If claim rework is eating your billing team’s week, book a demo and see how Pabau follows every submitted claim through to payment.

Continue your research

Want to cut drug claim denials across the practice? Denial management in healthcare covers how to track, appeal and prevent the rejections that repeat most often.

Need a primer on what medical billing involves end to end? What is medical billing walks through the revenue cycle from patient registration to payment posting.

Submitting 837P files and unsure what a clean claim needs? Clean claim requirements breaks down every required field, including NDC placement for drug lines.

Reading remittance and want the denial pattern faster? Electronic remittance advice explains how to read an ERA and sort denials by reason code.

Worried an audit would find your documentation thin? Medical billing compliance sets out what to keep, who signs it, and how long to hold it.

Frequently asked questions